A new compound developed for use with other two drugs to treat the deadliest strain of tuberculosis (TB) has been approved by the US Food and Drug Administration.
- The antibiotic, called pretamonid, was developed by TB Alliance as part of a three-drug regimen
- Pretomanid in combination with bedaquiline and linezolid has been shown to treat extensively drug-resistant TB and other resistant forms of the disease
- Tuberculosis, a contagious infection that usually attacks the lungs, claims 1.6 million people worldwide every year
Read the full text TimesNow